Angiotensin-converting enzyme inhibition and food restriction restore delayed preconditioning in diabetic mice

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Van der Mieren, Gerry ^a   Nevelsteen, Ines ^a   Vanderper, Annelies ^a   Oosterlinck, Wouter ^a   Flameng, Willem ^a   Herijgers, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Diabetes mellitus; Ischemia reperfusion injury; Metabolic syndrome; Myocardial protection; Preconditioning

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART PROTECTION; ISCHEMIC PRECONDITIONING; KNOCKOUT MOUSE; LEPTIN DEFICIENCY; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; REPERFUSION; SHAM PROCEDURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CALORIC RESTRICTION; DIABETES MELLITUS, EXPERIMENTAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; TIME FACTORS;

EID: 84874070114     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-36     Document Type: Article

References (34)

1. Bolli R, Li QH, Tang XL, Guo Y, Xuan YT, Rokosh G, Dawn B. The late phase of preconditioning and its natural clinical application-gene therapy. Heart Fail Rev 2007, 12:189-199.
2. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 2007, 59:418-458.
3. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012, 11:67.
4. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann Thorac Surg 2003, 75:S709-714.
5. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-2364.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
7. Dohi T, Miyauchi K, Kasai T, Kajimoto K, Kubota N, Tamura H, Yokoyama T, Kojima T, Yokoyama K, Kurata T, Daida H. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009, 73:1454-1458.
8. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
9. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
10. Van der Mieren G, Van den Bergh A, Nevelsteen I, Vanderper A, Flameng W, Herijgers P. Hypoxic preconditioning preserves cardiac contractility and reduces infarct size in vivo. The Open Surgery Journal 2008, 2:24-29.
11. Ebel D, Müllenheim J, Frässdorf J, Heinen A, Huhn R, Bohlen T, Ferrari J, Südkamp H, Preckel B, Schlack W, Thämer V. Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. Pflugers Arch 2003, 446:175-182.
12. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, . American Heart Association; American Diabetes Association Primary prevention of cardiovascular disease in people with diabetes mellitus. A Scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126. American Heart Association; American Diabetes Association.
13. Abete P, Testa G, Galizia G, Mazzella F, Della Morte D, de Santis D, Calabrese C, Cacciatore F, Gargiulo G, Ferrara N, Rengo G, Sica V, Napoli C, Rengo F. Tandem action of exercise training and food restriction completely preserves ischemic preconditioning in the aging heart. Exp Gerontol 2005, 40:43-50.
14. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004, 110:3259-3269.
15. Miki T, Miura T, Ura N, Ogawa T, Suzuki K, Shimamoto K, Limura O. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J Am Coll Cardiol 1996, 28:1616-1622.
16. Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K. Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovac Drugs Ther 1999, 13:151-157.
17. Jaberansari MT, Baxter GF, Muller CA, Latouf SE, Röth E, Opie LH, Yellon DM. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. J Am Coll Cardiol 2001, 37:1996-2001.
18. Marktanner R, Nacke P, Feindt P, Hohlfeld T, Schipke JD, Gams E. Delayed preconditioning via Angiotensin-converting enzyme inhibition: pros and cons from an experimental study. Clin Exp Pharmacol Physiol 2006, 33:787-792.
19. Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism 1998, 47:7-11.
20. Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P. Dyslipidemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res 2008, 77:371-379.
21. Van der Mieren G, Nevelsteen I, Vanderper A, Oosterlinck W, Flameng W, Herijgers P. Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury. Cardiovasc Diabetol 2012, 11:89.
22. Wichi R, Farah V, Chen Y, Irigoyen MC, Morris M. Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2007, 292:R1184-1189.
23. Van den Bergh A, Flameng W, Herijgers P. Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state. Pflugers Arch 2008, 455:987-994.
24. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006, 98:596-605.
25. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
26. Guo Y, Sanganalmath SK, Wu W, Zhu X, Huang Y, Tan W, Ildstad ST, Li Q, Bolli R. Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol 2012, 107:1-8.
27. Natali A, Ferrannini E. Endothelial dysfunction in type 2 diabetes. Diabetologia 2012, 55:1559-1563.
28. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, D'Amico M. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004, 53:454-462.
29. Marfella R, Esposito K, Nappo F, Siniscalchi M, Sasso FC, Portoghese M, Di Marino MP, Baldi A, Cuzzocrea S, Di Filippo C, Barboso G, Baldi F, Rossi F, D'Amico M, Giugliano D. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004, 53:2383-2391.
30. Das DK, Maulik N. Cardiac genomic response following preconditioning stimulus. Cardiovasc Res 2006, 70:254-263.
31. Halestrap AP, Clarke SJ, Javadov A. Mitochondrial permeability transition pore opening during myocardial reperfusion- a target for cardioprotection. Cardiovasc Res 2004, 61:372-385.
32. Abete P, Cacciatore F, Testa G, Della-Morte D, Galizia G, de Santis D, Calabrese C, Cioppa A, Ferrara N, Rengo F. Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev 2010, 9:153-162.
33. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R. Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 2001, 33:395-403.
34. Sohal RS, Ku HH, Agarwal S, Forster MJ, Lal H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech Ageing Dev 1994, 74:121-133.